


















Inhaler Devices Identification Chart

Short Acting Beta Agonists (SABA)			Short Acting Muscarinic Antagonists (SAMA)	Combination SABA + SAMA	RELIEVERS
SALBUTAMOL Respigen® SalAir® Ventolin®  Funded Funded Partially funded 100 mcg - Aerosol inhaler			TERBUTALINE ^{Funded} Bricanyl®  250mcg – Turbuhaler®	IPRATROPIUM ^{Funded} Atrovent®  20mcg - Aerosol inhaler	
Inhaled Corticosteroids (ICS)					
FLUTICASONE propionate ^{Funded} Floair® (not funded from 1st Sept 2020) Flixotide®  50mcg 125mcg 250mcg 50mcg 125mcg 250mcg 50mcg 100mcg 250mcg Aerosol inhaler Accuhaler®			BUDESONIDE ^{Funded} Pulmicort®  100mcg 200mcg 400mcg Turbuhaler®	BECLOMETHASONE dipropionate ^{Funded} Beclazone® Qvar® (ultrafineparticle)  50mcg 100mcg 250mcg 50mcg 100mcg Note. Beclazone® & Qvar® are <i>not</i> dose equivalent and are not interchangeable	
Combination Inhaled Corticosteroids (ICS) + Long Acting Beta2 Agonists (LABA)					
FLUTICASONE propionate + SALMETEROL ^{Funded} RexAir® (not funded from 1st of Sept 2020) Seretide®  50/25 125/25 250/25* *250/25 not funded Aerosol inhaler			FLUTICASONE furoate + VILANTEROL ^{Funded} Breo Ellipta®  100mcg/25mcg Dry powdered inhaler	BUDESONIDE + FORMOTEROL ^{Funded} Symbicort® Vannair®  100/6 200/6 400/12* *Only funded if no more than 2 doses per day Turbuhaler® Aerosol inhaler	

Inhaler Devices Identification Chart

Long Acting Beta2 Agonists (LABA)					
<p>SALMETEROL Funded</p> <p>Meterol® Serevent®</p>		<p>FORMOTEROL (eformoterol) Partially funded</p> <p>Oxis® Foradil®</p>		<p>INDACATEROL Funded</p> <p>Onbrez Breezhaler®</p>	
					
<p>25mcg 25mcg</p> <p>Aerosol inhaler Accuhaler®</p>		<p>6mcg 12mcg</p> <p>Turbuhaler® Aerolizer device®</p>		<p>150mcg 300mcg</p> <p>Breezhaler®</p>	
Long Acting Muscarinic Antagonists (LAMA)			Combination Long Acting Muscarinic Antagonists (LAMA) + Long Acting Beta2 Agonists (LABA)		
<p>Funded by Endorsement: LAMA inhaler is subsidised only for patients who have been diagnosed as having COPD using spirometry, and the prescription is endorsed accordingly (i.e. COPD documented as indication on prescription).</p>			<p>Funded via Special Authority: LAMA + LABA inhaler is subsidised only for patient who has been stabilised on a LAMA and the prescriber considers that the patient would receive additional benefit from switching to a combination product.</p>		
<p>TIOTROPIUM</p> <p>Spiriva® Spiriva Respimat®</p>		<p>UMECLIDINIUM</p> <p>Incruse Ellipta®</p>	<p>GLYCOPYRRONIUM</p> <p>Seebri®</p>	<p>TIOTROPIUM + OLODATEROL</p> <p>Spiolto Respimat®</p>	<p>UMECLIDINIUM + VILANTEROL</p> <p>Anoro Ellipta®</p>
					
<p>18mcg 2.5mcg</p> <p>Handihaler® Fine mist inhaler</p>		<p>62.5mcg</p> <p>Dry powdered inhaler</p>	<p>50mcg</p> <p>Breezhaler®</p>	<p>2.5mcg/2.5mcg</p> <p>Fine mist inhaler</p>	<p>62.5 mcg/25 mcg</p> <p>Dry powdered inhaler</p>
					<p>50 mcg/110 mcg</p> <p>Breezhaler®</p>
<p>NOTE</p> <p>Inhalers not depicted include Mast Cell Stabilisers including: SODIUM CROMOGLYCATE inhaler (Intal Forte® 5mg/puff) and NEDOCROMIL aerosol inhaler (Tilade 2mg/actuation)</p>					

LONG-ACTING SYMPTOM CONTROLLERS (for COPD)